HealthQuill FDA
The US Food and Drug Administration has approved Johnson & Johnson’s nasal spray in adults who have had an inadequate response to at least two oral antidepressants for treating major depressive disorder.
Uncategorized

J&J’s nasal spray to treat major depressive disorder gets FDA nod

The US Food and Drug Administration has approved Johnson & Johnson’s nasal spray in adults who have had an inadequate response to at.

Read More
Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from the Japanese company.
Drugs Health Pharma

Daiichi Sankyo to buy cancer antibody from Glycotope for $132.5 million

Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from.

Read More
ohnson & Johnson paused its rollout of a heart device to treat atrial fibrillation “out of an abundance of caution,” as it probes four cases of neurovascular events related to the device.
Health Medical Pharma

J&J pauses rollout of heart device in US after ischemic, stroke incidents

ohnson & Johnson paused its rollout of a heart device to treat atrial fibrillation “out of an abundance of caution,” as it probes four.

Read More
Pneumonia is a form of acute respiratory infection that affects the lungs and kills more children than any other infectious disease. Every day at least one child dies from pneumonia every 43 seconds, according to UNICEF.
Drugs Health Medical

FDA halts RSV vaccine trials for infants amid safety concerns

HQ Team December 11, 2024: The U.S. Food and Drug Administration (FDA) has announced a halt to all clinical trials for respiratory syncytial.

Read More
AstraZeneca Plc’s drug Fasenra got approval from the European Union regulator for treating adult patients with a rare inflammation of blood vessels.
Drugs Health Pharma

AstraZeneca’s drug to treat rare blood vessel disease gets EU nod

AstraZeneca Plc’s drug Fasenra got approval from the European Union regulator for treating adult patients with a rare inflammation of blood vessels.

Read More
Multiple US agencies are investigating an outbreak of E. coli in the country, which was reported after eating Quarter Pounders hamburgers at McDonald’s, as cases rise in new states.
Drugs Health Pharma

E.coli illness caused by McDonald’s Quarter Pounder rise in the US

Multiple US agencies are investigating an outbreak of E. coli in the country, which was reported after eating Quarter Pounders hamburgers at McDonald’s,.

Read More
Astellas Pharma Inc.’s therapy to treat a form of gastric cancer got approval from the US drug regulator, according to a company statement.
Drugs Health Pharma

Astellas Pharma gets US regulator’s nod for its gastric cancer drug 

Astellas Pharma Inc.’s therapy to treat a form of gastric cancer got approval from the US drug regulator, according to a company statement.

Read More
Gilead Sciences, Inc. has withdrawn its bladder cancer drug from the US market and stopped its confirmatory clinical trial after it failed to extend the lives of patients who had undergone prior treatments.
Drugs Health Pharma

Gilead’s end-stage confirmatory trials of bladder cancer drug fail

Gilead Sciences, Inc. has withdrawn its bladder cancer drug from the US market and stopped its confirmatory clinical trial after it failed to.

Read More
British-Swedish AstraZeneca’s drug for treatment of a form of blood cancer has been granted a Priority Review in the US by the drug regulator.
Drugs Health Pharma

AstraZeneca’s experimental blood cancer drug gets US priority review

British-Swedish AstraZeneca’s drug for treatment of a form of blood cancer has been granted a Priority Review in the US by the drug.

Read More
Gilead Sciences, Inc. has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical makers to make and sell its generic lenacapavir drug for the prevention of HIV.
Drugs Health Pharma

Gilead signs six global pacts to make, sell generic HIV preventive drug

Gilead Sciences, Inc. has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical makers to make and sell its generic lenacapavir drug for the prevention.

Read More